Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month High - Here's Why

Key Points

• CRL reached a new 52-week high, trading as high as $288.64 and closing well above its 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating from 16 analysts and an average price target of $255.65, although recent ratings ranged from “overweight” to “hold” and “sell.”
• Charles River exceeded quarterly expectations with adjusted EPS of $3.02 versus the $2.77 consensus and revenue of $1.0 billion, but revenue declined 2.7% year over year; insiders have sold about $31.8 million of shares over the past 90 days.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The company traded as high as $288.64 and last traded at $288.4150, with a volume of 350686 shares traded. The stock had previously closed at $280.05.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 1st. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Citigroup reiterated a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, CLSA downgraded Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a research report on Monday, July 20th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $255.65.

Charles River Laboratories International Stock Up 2.8%

The business's fifty day simple moving average is $224.87 and its 200 day simple moving average is $191.11. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of -59.36, a price-to-earnings-growth ratio of 2.90 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm's revenue was down 2.7% on a year-over-year basis. During the same period last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, CEO Birgit Girshick sold 6,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares in the company, valued at approximately $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 129,817 shares of company stock worth $31,774,935 over the last ninety days. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Several large investors have recently modified their holdings of CRL. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at approximately $42,000. Sfam LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at approximately $43,000. Activest Wealth Management boosted its holdings in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company's stock valued at $44,000 after buying an additional 218 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock worth $44,000 after acquiring an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $46,000. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source